Forte Biosciences, Inc. (FBRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Forte Biosciences, Inc. (FBRX) trades at $20.50 with AI Score 24/100 (Grade F). Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Market cap: $284.67M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for FBRX: FBRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FBRX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FBRX: 1/1 perspectives are bearish.
How is this calculated? →Forte Biosciences, Inc. (FBRX) Healthcare & Pipeline Overview
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing FB-102, a novel therapy targeting autoimmune diseases like vitiligo and alopecia areata. Headquartered in Dallas, Texas, the company aims to address unmet needs in dermatology and immunology through innovative therapeutic solutions.
What Is the Investment Thesis for FBRX?
Forte Biosciences, Inc. presents a focused investment opportunity within the biotechnology sector, primarily driven by the development of FB-102, a therapeutic program targeting autoimmune diseases like vitiligo and alopecia areata. The company's potential lies in the successful clinical development and commercialization of FB-102, addressing unmet needs in dermatology and immunology. Key value drivers include positive clinical trial results, regulatory approvals, and strategic partnerships. However, the investment is subject to risks inherent in clinical-stage biopharmaceutical companies, including clinical trial failures, regulatory hurdles, and competition from existing and emerging therapies. The company's financial performance is heavily dependent on the success of FB-102, making it a high-risk, high-reward investment. As of 2026-05-10, Forte Biosciences has a market capitalization of $284.67M and a beta of 3.20, indicating significant market volatility.
Based on FMP financials and quantitative analysis
FBRX Key Highlights
- Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune diseases.
- The lead program, FB-102, targets vitiligo and alopecia areata.
- The company is headquartered in Dallas, Texas.
- Forte Biosciences has a market capitalization of $284.67M as of 2026-05-10.
- The company's beta is 3.20, indicating high volatility.
Who Are FBRX's Competitors?
FBRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FBRX's Key Strengths?
- Focus on autoimmune diseases with unmet needs.
- Proprietary FB-102 program.
- Experienced management team.
- Strong intellectual property position.
What Are FBRX's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on the success of FB-102.
- Limited financial resources.
- High cash burn rate.
What Could Drive FBRX Stock Higher?
- Clinical trial data readouts for FB-102 in vitiligo and alopecia areata.
- Potential FDA submission for FB-102.
- Strategic partnership discussions with pharmaceutical companies.
- Expansion into new autoimmune disease indications.
What Are the Key Risks for FBRX?
- Financial-distress signal — its Altman Z-Score of -1.09 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for FB-102.
- Regulatory delays or rejection from the FDA.
- Competition from existing and emerging therapies.
- Financial risks associated with funding clinical development.
What Are the Growth Opportunities for FBRX?
- Successful Clinical Trials: The successful completion of clinical trials for FB-102 represents a significant growth opportunity for Forte Biosciences. Positive clinical data demonstrating the safety and efficacy of FB-102 in treating vitiligo and alopecia areata could lead to regulatory approval and commercialization. The market for vitiligo and alopecia areata treatments is estimated to reach billions of dollars, providing a substantial revenue opportunity for Forte Biosciences upon successful product launch. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
- Regulatory Approval: Obtaining regulatory approval from the FDA for FB-102 is a critical milestone that would unlock significant value for Forte Biosciences. Regulatory approval would allow the company to market and sell FB-102 in the United States, the largest pharmaceutical market in the world. The regulatory pathway for autoimmune disease therapies is well-defined, providing Forte Biosciences with a clear roadmap for achieving regulatory success. Timeline: Potential FDA submission within the next 2-3 years, pending clinical trial results.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies could accelerate the development and commercialization of FB-102. Partnerships could provide Forte Biosciences with access to additional funding, expertise, and resources, enhancing its ability to navigate the complex regulatory and commercial landscape. Strategic partnerships could also expand the market reach of FB-102, increasing its potential for commercial success. Timeline: Ongoing discussions with potential partners, with potential agreements in the next 12-18 months.
- Expansion into New Indications: Expanding the application of FB-102 to other autoimmune diseases represents a significant growth opportunity for Forte Biosciences. The underlying mechanism of action of FB-102 may be applicable to a range of autoimmune conditions, allowing the company to leverage its existing research and development efforts to address additional unmet needs. Expanding into new indications could significantly increase the market potential of FB-102. Timeline: Potential expansion into new indications within the next 3-5 years, following successful clinical development in vitiligo and alopecia areata.
- Market Penetration: Achieving strong market penetration following the commercial launch of FB-102 is essential for maximizing its revenue potential. Effective marketing and sales strategies, combined with a strong distribution network, will be critical for capturing market share and establishing FB-102 as a leading therapy for vitiligo and alopecia areata. Successful market penetration could drive significant revenue growth for Forte Biosciences. Timeline: Ongoing preparations for commercial launch, with potential product launch within the next 2-3 years, pending regulatory approval.
What Opportunities Does FBRX Have?
- Successful clinical trial results for FB-102.
- Regulatory approval from the FDA.
- Strategic partnerships with established pharmaceutical companies.
- Expansion into new autoimmune disease indications.
What Threats Does FBRX Face?
- Clinical trial failures.
- Regulatory delays or rejection.
- Competition from existing and emerging therapies.
- Patent challenges.
What Are FBRX's Competitive Advantages?
- Proprietary FB-102 program.
- Intellectual property protection through patents.
- Clinical data supporting safety and efficacy.
- Expertise in autoimmune disease drug development.
What Does FBRX Do?
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for autoimmune diseases. The company's primary focus is on FB-102, a proprietary program designed to address various autoimmune conditions, including vitiligo and alopecia areata. Founded with the mission of providing innovative solutions for patients suffering from debilitating autoimmune disorders, Forte Biosciences is committed to advancing scientific research and clinical development to improve patient outcomes. Forte Biosciences operates primarily in the United States, conducting research and development activities to support the advancement of FB-102 through clinical trials. The company's strategy involves identifying and developing therapies that target the underlying mechanisms of autoimmune diseases, with the goal of achieving meaningful clinical benefits for patients. With a focus on dermatology and immunology, Forte Biosciences aims to establish a leading position in the development of innovative treatments for autoimmune conditions. Headquartered in Dallas, Texas, Forte Biosciences is led by a team of experienced professionals with expertise in drug development, clinical research, and commercialization. The company's leadership is dedicated to driving the development of FB-102 and expanding its pipeline of novel therapies for autoimmune diseases. Forte Biosciences is committed to building strong partnerships with key stakeholders, including researchers, clinicians, and patient advocacy groups, to advance its mission of improving the lives of patients with autoimmune disorders.
What Products and Services Does FBRX Offer?
- Develops therapies for autoimmune diseases.
- Focuses on FB-102 program.
- Targets vitiligo and alopecia areata.
- Conducts clinical trials to evaluate drug efficacy.
- Seeks regulatory approval for its therapies.
- Aims to commercialize innovative treatments.
How Does FBRX Make Money?
- Develops and patents novel therapeutic programs.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved therapies through sales and marketing.
What Industry Does FBRX Operate In?
Forte Biosciences operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory oversight, and substantial investment in research and development. The company's focus on autoimmune diseases aligns with the growing prevalence of these conditions and the increasing demand for effective therapies. The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms, all vying for market share in the autoimmune disease treatment space. The biotechnology industry is subject to stringent regulatory requirements, with the FDA playing a critical role in the approval and commercialization of new therapies.
Who Are FBRX's Key Customers?
- Patients suffering from autoimmune diseases.
- Dermatologists and other healthcare providers.
- Pharmacies and hospitals.
- Healthcare payers (insurance companies).
How Forte Biosciences, Inc. Is Valued
Forte Biosciences, Inc. carries a market capitalization of $284.67M, placing it in the micro-cap category. Relative to its peer group, FBRX's quantitative score of 24/100 is below the peer average of 76/100.
Key Financial Metrics
Its free cash flow yield is -20.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Forte Biosciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.09 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Forte Biosciences, Inc. revenue of about $9.0M for fiscal 2026, with EPS near $-4.11. The estimate reflects 4 contributing analysts.
FBRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence from management about the company's future prospects.
- Community sentiment has shifted positively as new clinical trial results show promise, sparking increased interest.
- Growing discussions around potential partnerships indicate a favorable market perception and optimism about product development.
- The company has been actively engaging with investors, fostering a sense of transparency and trust within the trading community.
Bear Case
- Concerns over the competitive landscape in the biotech sector may dampen enthusiasm for Forte's offerings.
- Recent social sentiment has shown some volatility, reflecting uncertainty among investors regarding the company's long-term viability.
- Skepticism remains about the timeline for product approvals, leading to cautious sentiment in the trading community.
- Insider selling activity in the past has raised red flags, causing some investors to question the company's stability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FBRX Latest News
No recent news available for FBRX.
FBRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FBRX.
Price Targets
Wall Street price target analysis for FBRX.
FBRX MoonshotScore
What does this score mean?
The MoonshotScore rates FBRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul A. Wagner
CEO
Paul A. Wagner serves as the Chief Executive Officer of Forte Biosciences, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at various biotechnology companies, overseeing clinical trials, regulatory submissions, and product launches. Wagner's expertise spans multiple therapeutic areas, including dermatology and immunology. He is responsible for guiding Forte Biosciences' strategic direction and driving the development of FB-102.
Track Record: Under Paul A. Wagner's leadership, Forte Biosciences has advanced the development of FB-102, progressing through clinical trials and preparing for potential regulatory submissions. He has focused on building a strong team and securing partnerships to support the company's growth. Key milestones include initiating and completing clinical trials for FB-102 and establishing collaborations with leading researchers and clinicians.
FBRX Healthcare Stock FAQ
What does Forte Biosciences, Inc. do?
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases. The company's lead program, FB-102, targets conditions such as vitiligo and alopecia areata. Forte Biosciences aims to address unmet needs in dermatology and immunology by developing innovative treatments that improve patient outcomes. The company's strategy involves conducting clinical trials, seeking regulatory approval, and commercializing its therapies through sales and marketing efforts.
What do analysts say about FBRX stock?
Analyst coverage of Forte Biosciences, Inc. (FBRX) typically focuses on the potential of its lead program, FB-102, and its prospects for regulatory approval and commercial success. Key valuation metrics include market capitalization, cash burn rate, and potential revenue from FB-102. Growth considerations include the successful completion of clinical trials, regulatory milestones, and strategic partnerships. Analyst consensus may vary depending on the perceived risk and potential reward associated with Forte Biosciences' clinical development programs. This is not a buy or sell recommendation.
What are the main risks for FBRX?
The main risks for Forte Biosciences, Inc. include the inherent uncertainties associated with clinical-stage drug development. Clinical trial failures, regulatory delays or rejection, and competition from existing and emerging therapies pose significant challenges. Financial risks include the need for additional funding to support clinical development and the potential for dilution of shareholder value. The company's reliance on the success of FB-102 also represents a significant risk.
What are the key factors to evaluate for FBRX?
Forte Biosciences, Inc. (FBRX) holds an AI score of 24/100 (low). Not financial advice.
How frequently does FBRX data refresh on this page?
FBRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FBRX's recent stock price performance?
Forte Biosciences, Inc. (FBRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on autoimmune diseases with unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBRX overvalued or undervalued right now?
Valuing Forte Biosciences, Inc. (FBRX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FBRX?
Before investing in Forte Biosciences, Inc. (FBRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain.
- Regulatory approvals are subject to change.